10-Q Filing

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC CIK: 1730430 Q1 2020

Filing Information

Form Type	10-Q
Accession Number	`0001558370-20-005040`
Period End Date	20200331
Filing Date	20200504
Fiscal Year	2020
Fiscal Period	Q1
XBRL Instance	knsa-20200331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 47 Income Statement 28 Cash Flow Statement 51 Stockholders Equity 17

Balance Sheet 47 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$46.93M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$106.34M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$97.87M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$186.45M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$8.25M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$8.85M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$241.63M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$213.06M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.40M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$5.80M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$1.93M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$1.63M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$4.37M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$5.41M	USD	Point-in-time
Total assets	`Assets`	$226.11M	USD	Point-in-time
Total assets	`Assets`	$254.53M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$4.27M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.69M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$13.38M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$20.41M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.69M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.70M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$25.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$19.34M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$27.83M	USD	Point-in-time
Non-current operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$551.00K	USD	Point-in-time
Non-current operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$955.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$326.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$381.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$29.11M	USD	Point-in-time
Total liabilities	`Liabilities`	$20.27M	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$581.47M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$588.09M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$240.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$33.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-382.51M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-356.09M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$225.42M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$279.27M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$205.83M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$306.52M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$226.11M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$254.53M	USD	Point-in-time

Income Statement 28 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$20.90M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$59.25M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$8.39M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$8.49M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$29.39M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$67.65M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-29.39M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-67.65M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$789.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.81M	USD	1 Quarter
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-65.84M	USD	1 Quarter
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-28.60M	USD	1 Quarter
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-17.00K	USD	1 Quarter
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-2.18M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-26.42M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Net loss per share attributable to common shareholdersbasic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.48	USD	1 Quarter
Net loss per share attributable to common shareholdersbasic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.27	USD	1 Quarter
Weighted average common shares outstandingbasic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	51.76M	shares	1 Quarter
Weighted average common shares outstandingbasic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	55.32M	shares	1 Quarter
Net loss	`NetIncomeLoss`	$-26.42M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Unrealized gain on short-term investments and currency translation adjustments, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$207.00K	USD	1 Quarter
Unrealized gain on short-term investments and currency translation adjustments, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.00K	USD	1 Quarter
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$207.00K	USD	1 Quarter
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$12.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-65.81M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-26.21M	USD	1 Quarter

Cash Flow Statement 51 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-26.42M	USD	1 Quarter
Net loss	`ProfitLoss`	$-65.82M	USD	1 Quarter
Depreciation expense	`Depreciation`	$594.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$471.00K	USD	1 Quarter
Share-based compensation expense	`ShareBasedCompensation`	$2.89M	USD	1 Quarter
Share-based compensation expense	`ShareBasedCompensation`	$4.21M	USD	1 Quarter
Class A common shares issued or to be issued as consideration for Primatope, including milestone payments	`IssuanceOfStockForAcquisition`	$7.00M	USD	1 Quarter
Non-cash lease expense	`NoncashLeaseExpense`	$300.00K	USD	1 Quarter
Non-cash lease expense	`NoncashLeaseExpense`	$334.00K	USD	1 Quarter
Accretion of discounts on short-term investments	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$228.00K	USD	1 Quarter
Accretion of discounts on short-term investments	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$846.00K	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.04M	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-240.00K	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$598.00K	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.54M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-1.20M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-3.34M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-7.06M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-376.00K	USD	1 Quarter
Accrued milestones	`IncreaseDecreaseInAccruedMilestone`	$-2.00M	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-293.00K	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-413.00K	USD	1 Quarter
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$509.00K	USD	1 Quarter
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$55.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-31.80M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-63.26M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$223.00K	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.56M	USD	1 Quarter
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$26.19M	USD	1 Quarter
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$181.81M	USD	1 Quarter
Proceeds from the maturities of short-term investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments`	$115.20M	USD	1 Quarter
Proceeds from the maturities of short-term investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments`	$174.09M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$88.79M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-9.28M	USD	1 Quarter
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$100.00K	USD	1 Quarter
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$2.41M	USD	1 Quarter
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$181.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$83.19M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.41M	USD	1 Quarter
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$10.65M	USD	1 Quarter
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$59.41M	USD	1 Quarter
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.14M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$106.55M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$82.84M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.14M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$106.55M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$82.84M	USD	Point-in-time
Deferred offering costs included in accrued expenses and accounts payable	`DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable`	$19.00K	USD	1 Quarter
Property and equipment included in accrued expenses and accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$37.00K	USD	1 Quarter

Stockholders Equity 17 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of the period	`StockholdersEquity`	$225.42M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$205.83M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$306.52M	USD	Point-in-time
Common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.	`StockIssuedDuringPeriodValueAcquisitions`	$7.00M	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$181.00K	USD	1 Quarter
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.41M	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$2.89M	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.21M	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$207.00K	USD	1 Quarter
Unrealized gain on short-term investments	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-26.42M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-65.82M	USD	1 Quarter
Balance at the end of the period	`StockholdersEquity`	$205.83M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$225.42M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$306.52M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.